| abstract |
The present description relates to anti-CD200 antibodies (eg, anti-CD200 variant antibodies that have reduced or no effector function) and biomarkers for use in a variety of diagnostic and therapeutic methods, for example, to determine whether a In human beings one or more of the antibodies have been administered at a dose sufficient to induce a desired immunomodulation effect in humans and to select an appropriate dosage schedule for a patient. |